IceCure Medical Ltd. (NASDAQ:ICCM) Q1 2022 Earnings Conference Call May 18, 2022 8:30 AM ET
Company Participants
Eyal Shamir - Chief Executive Officer
Ronen Tsimerman - Chief Financial Officer and Chief Operating Officer
Richard Fine - Investigator of ICE3 Clinical Trial
Conference Call Participants
Ben Haynor - Alliance Global Partners
Kemp Dolliver - Brookline Capital Markets
Operator
Welcome to IceCure’s First Quarter 2022 Results Conference Call. Management will provide an overview of IceCure’s financial results as well as clinical and operational highlights.
On the call today are IceCure’s CEO, Eyal Shamir and CFO, Ronen Tsimerman. They are joined today by Dr. Richard Fine. Dr. Fine is a trial investigator for IceCure’s ICE3 clinical trial on cryoablation of small Low-Risk Breast cancer. Dr. Fine is also a past President and Chairman of the American Society of American Society of Breast Surgeons, Program Director of the Breast Surgical Oncology Fellowship and Director of Research and Education at the West Comprehensive Breast Center in Germantown, Tennessee.
Following the presentation, IceCure’s management and Dr. Fine will be available for a question and answer session. I will now take a brief moment to read the Safe Harbor statement. This presentation contains forward-looking statements within the meaning of the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. Words such as "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates" and similar expressions or variations of such words are intended to identify forward-looking statements. For example, IceCure is using the forward-looking statement in this press release when it discusses pursuit of regulatory approvals and FDA review, strategic plans, commercial growth, expansion of clinical applications with its minimally-invasive cryoablation technology, advancing regulatory and commercial strategies and expected quarter-over-quarter revenue variations for future periods. Because such statements deal with future events and are based on IceCure's current expectations, they are subject to various risks and uncertainties and actual results, performance, or achievements of IceCure could differ materially from those described in or implied by the statements in this presentation. The forward-looking statements contained or implied in this presentation are subject to other risks and uncertainties, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Company's Annual Report on Form 20-F for the year ending December 31, 2021 filed with the SEC on April 1, 2022, which is available on the SEC's website, www.sec.gov. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.